User menu

Dose-escalation study using up to twice the standard dose of cetuximab in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST study): Preliminary data.

Bibliographic reference Tejpar, Sabine ; Humblet, Yves ; Peeters, Marie-Rose ; Gelderblom, H. ; Vermorken, J. ; et. al. Dose-escalation study using up to twice the standard dose of cetuximab in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST study): Preliminary data..42nd Annual Meeting of the American-Society-of-Clinical-Oncology (Atlanta (Ga), Jun 02-06, 2006). In: Journal of Clinical Oncology, Vol. 24, no. 18, p. 159S-159S (2006)
Permanent URL http://hdl.handle.net/2078.1/59894